Barclays PLC Sells 9,126 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Barclays PLC lessened its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 15.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 50,081 shares of the medical instruments supplier's stock after selling 9,126 shares during the period. Barclays PLC owned 0.20% of ICU Medical worth $7,771,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Sterling Capital Management LLC grew its holdings in shares of ICU Medical by 813.5% in the fourth quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier's stock worth $105,000 after acquiring an additional 602 shares during the period. CenterBook Partners LP purchased a new position in ICU Medical in the 4th quarter worth about $1,467,000. Martingale Asset Management L P raised its holdings in shares of ICU Medical by 1,100.0% in the fourth quarter. Martingale Asset Management L P now owns 16,800 shares of the medical instruments supplier's stock valued at $2,607,000 after acquiring an additional 15,400 shares in the last quarter. Invesco Ltd. increased its holdings in shares of ICU Medical by 12.4% in the 4th quarter. Invesco Ltd. now owns 113,153 shares of the medical instruments supplier's stock valued at $17,558,000 after acquiring an additional 12,489 shares during the period. Finally, Bank of Montreal Can raised its stake in ICU Medical by 5.4% in the fourth quarter. Bank of Montreal Can now owns 4,051 shares of the medical instruments supplier's stock valued at $629,000 after buying an additional 208 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.

Wall Street Analysts Forecast Growth

ICUI has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research report on Tuesday, April 8th. StockNews.com cut ICU Medical from a "buy" rating to a "hold" rating in a research note on Thursday, April 24th. KeyCorp reduced their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Finally, Raymond James set a $97.00 price target on ICU Medical in a report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ICU Medical currently has an average rating of "Moderate Buy" and an average target price of $162.67.

ICU Medical Price Performance

Shares of ICU Medical stock traded up $0.43 during trading on Tuesday, hitting $136.33. The stock had a trading volume of 14,779 shares, compared to its average volume of 273,077. The firm has a market cap of $3.35 billion, a P/E ratio of -29.77 and a beta of 0.86. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The business has a fifty day moving average of $143.25 and a two-hundred day moving average of $157.64. ICU Medical, Inc. has a fifty-two week low of $95.44 and a fifty-two week high of $196.26.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.